<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor vorinostat is a candidate radiosensitizer in locally advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> (LARC) </plain></SENT>
<SENT sid="1" pm="."><plain>Radiosensitivity is critically influenced by <z:mp ids='MP_0005039'>hypoxia</z:mp>; hence, it is important to evaluate the efficacy of potential radiosensitizers under variable tissue oxygenation </plain></SENT>
<SENT sid="2" pm="."><plain>Since fluoropyrimidine-based chemoradiotherapy (CRT) is the only clinically validated regimen in LARC, efficacy in combination with this established regimen should be assessed in preclinical models before a candidate drug enters clinical trials </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Radiosensitization by vorinostat under <z:mp ids='MP_0005039'>hypoxia</z:mp> was studied in four colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cell lines and in one colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> by analysis of clonogenic survival and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0001510'>growth delay</z:hpo>, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Radiosensitizing effects of vorinostat in combination with <z:chebi fb="0" ids="31348">capecitabine</z:chebi> were assessed by evaluation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0001510'>growth delay</z:hpo> in two colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenografts models</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Under <z:mp ids='MP_0005039'>hypoxia</z:mp>, radiosensitization by vorinostat was demonstrated in vitro in terms of decreased clonogenicity and in vivo as inhibition of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Adding vorinostat to <z:chebi fb="0" ids="31348">capecitabine</z:chebi>-based CRT increased radiosensitivity of xenografts in terms of inhibited <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Vorinostat sensitized colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells to radiation under <z:mp ids='MP_0005039'>hypoxia</z:mp> in vitro and in vivo and improved therapeutic efficacy in combination with <z:chebi fb="0" ids="31348">capecitabine</z:chebi>-based CRT in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>The results encourage implementation of vorinostat into CRT in LARC trials </plain></SENT>
</text></document>